COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer

Table 2 Effects of high COX-2 expression on breast cancer survival¹

	5-Year Multivariable Cox Regression³				10-Year Multivariable Cox Regression³
	H.R.	95% CI	p-value	N	H.R.	95% CI	p-value	N
All patients	1.82	1.07-3.10	0.028*	184	1.60	0.96-2.65	0.066	184
ER-negative	2.79	1.35-5.78	0.006*	81	2.72	1.36-5.41	0.004*	81
ER-positive	1.26	0.53-2.99	0.598	103	0.96	0.42-2.21	0.920	103
HER2-negative	1.50	0.77-2.94	0.237	121	1.37	0.73-2.56	0.331	121
HER2-positive²	3.39	1.24-9.21	0.017*	62	2.84	1.07-7.52	0.036*	62
ER-/HER2-	2.47	1.00-6.10	0.048*	61	2.34	1.01-5.41	0.047*	61
ER-/HER2+	5.95	1.01-34.9	0.048*	20	5.95³	1.01-34.9	0.048*	20
ER+/HER2-	0.73	0.21-2.58	0.626	60	0.64	0.18-2.20	0.474	60
ER+/HER2+	2.60	0.47-14.2	0.272	42	1.91	0.42-8.57	0.397	42

¹ High COX-2 expression (moderate to strong IHC) versus low COX-2 expression (absent to weak IHC).
² HER2-positive: moderate to high IHC. ³ Adjusted for age at diagnosis, race, TNM stage, tumor grade, chemotherapy and tumor ER and p53 mutation status. ³ No further deaths after 5 years. *p < 0.05

ISSN: 1471-2407